4.3 Article

A coffee enriched with guarana, selenium, and L-carnitine (GSC) has nutrigenomic effects on oxi-inflammatory markers of relapsing-remitting multiple sclerosis patients: A pilot study

Journal

MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 71, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2023.104515

Keywords

Inflammation; Oxidative stress; Food supplement; Cytokines; Neuroprotection; Autoimmune disease

Ask authors/readers for more resources

This pilot study aimed to investigate the effects of a guarana, selenium, and L-carnitine (GSC) based multi supplement on oxidative and inflammatory markers in patients with relapsing-remitting multiple sclerosis (RRMS). The results showed that a low concentration of GSC could decrease the levels of oxidized DNA and pro-inflammatory cytokines in RRMS patients. These findings support further research on the potential clinical benefits of GSC in not only MS patients, but also in other neurological conditions.
Relapsing-remitting multiple sclerosis (RRMS) is the most common clinical course of multiple sclerosis (MS), characterized by a chronic inflammatory state and elevated levels of oxidative markers. Food supplements with potential anti-inflammatory, antioxidant and neuroprotective effects have been tested as possible adjuvants in the treatment of MS. In this sense, this pilot study was carried out with the aim of verifying whether a minimum daily dose of a guarana, selenium and L-carnitine (GSC) based multi supplement, mixed in cappuccino-type coffee, administered for 12 weeks to 28 patients with RRMS could differentially modulate oxidative blood markers (lipoperoxidation, protein carbonylation and DNA oxidation) and inflammatory blood markers (protein levels of cytokines IL-1 beta, IL-6, TNF-alpha, IFN-gamma, IL-10, gene expression of these cytokines, and NLRP3 and CASP-1 molecules, and C-reactive protein levels). The results indicate that a low concentration of GSC is capable of decreasing the plasma levels of oxidized DNA and pro-inflammatory cytokines of RRMS patients. The results support further research into the action of GSC on clinical symptoms, not only in patients with MS, but also with other neurological conditions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available